What is SynTouch?
Headquartered in Los Angeles and established in 2008, SynTouch specializes in the development of sensor technology that replicates the human sense of touch. Its flagship product, the BioTac, is engineered to mimic the physical properties and sensory capabilities of a human fingertip, allowing robots to perceive texture, vibration, and force. This technology is essential for industries requiring high-fidelity tactile feedback, ranging from industrial automation to advanced medical robotics. By quantifying how products feel, SynTouch provides manufacturers with actionable data to optimize product design and performance, effectively bridging the gap between mechanical operation and human-like sensory perception.
How much funding has SynTouch raised?
SynTouch has raised a total of $275K across 2 funding rounds:
Debt
$150K
Debt
$125K
Debt (2020): $150K with participation from PPP
Debt (2021): $125K led by PPP
Key Investors in SynTouch
PPP
Public-Private Partnership
What's next for SynTouch?
With the successful completion of this late-stage funding round, SynTouch is well-positioned to accelerate the commercial deployment of its tactile instrumentation. The strategic focus will likely shift toward expanding the integration of BioTac sensors into broader industrial applications and enhancing the software ecosystem that interprets complex tactile data. As the demand for sophisticated robotic interaction grows, SynTouch is poised to capitalize on its unique intellectual property, potentially exploring new verticals in consumer electronics and prosthetic development. The company's trajectory suggests a transition from specialized research-oriented applications to widespread industrial adoption, cementing its status as a foundational player in the future of robotic sensory intelligence.
See full SynTouch company page
